Naveen Pemmaraju: Important new paper led by Alex Bataller and Tapan Kadia

Naveen Pemmaraju shared on X/Twitter:

“Important New paper just out in Blood Advances led by Dr. Alex Bataller and Dr. Tapan Kadia.
Prognostic risk signature in patients with AML treated with HMA and VEN.”

Read further.
Source: Naveen Pemmaraju/X

Naveen Pemmaraju holds multiple positions at the University of Texas MD Anderson Cancer Center, including Executive Director of Cancer Medicine, the Director of the Leukemia – Cancer Network, and Professor in the Department of Leukemia. He is also the Director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) program at the MDACC Leukemia Department.

Dr. Pemmaraju’s clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), myeloproliferative neoplasms (MPN) and acute myeloid Leukemia (AML). Dr. Pemmaraju is also a well-known social media influencer.